Ishimoto AK, Shah AA (2024) Screening and early treatment for osteoporosis: who are we missing under age 65? Maturitas 187:108044

PubMed  Google Scholar 

Taher AT, Musallam KM, Cappellini MD (2021) β-Thalassemias. Longo DL, editor. N Engl J Med.;384(8):727–43

Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al (2005) Survival and complications in Thalassemia. Ann N Y Acad Sci 1054:40–47

PubMed  Google Scholar 

Tuo Y, Li Y, Li Y et al (2024) Global, regional, and national burden of Thalassemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. EClinicalMedicine 72:102619

PubMed  PubMed Central  Google Scholar 

Bhardwaj A, Swe KMM, Sinha NK, Osunkwo I (2016) Treatment for osteoporosis in people with ß-thalassaemia. Cochrane Database Syst Rev 3:CD010429

PubMed  Google Scholar 

Di Paola A, Marrapodi MM, Di Martino M et al (2024) Bone Health Impairment in patients with hemoglobinopathies: from Biological bases to New possible therapeutic strategies. Int J Mol Sci 25(5):2902

PubMed  PubMed Central  Google Scholar 

Baldini M, Forti S, Marcon A, Ulivieri FM, Orsatti A, Tampieri B et al (2010) Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 89(12):1207–1213

PubMed  Google Scholar 

Canatan D (2013) The Thalassemia Center of Antalya State Hospital: 15 years of experience (1994 to 2008). J Pediatr Hematol Oncol 35(1):24–27

PubMed  Google Scholar 

Leung TF, Chu Y, Lee V, Cheng FWT, Leung WK, Shing MMK et al (2009) Long-Term effects of Pamidronate in Thalassemic patients with severe bone Mineral Density deficits. Hemoglobin 33(5):361–369

PubMed  Google Scholar 

Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N et al (2009) Bone disease in Thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543–557

PubMed  Google Scholar 

Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S et al (2008) Gender differences in the prevalence and severity of bone disease in Thalassaemia. Pediatr Endocrinol Rev 6(Suppl 1):116–122

PubMed  Google Scholar 

Fung EB, Harmatz PR, Milet M, Coates TD, Thompson AA, Ranalli M et al (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 43(1):162–168

PubMed  PubMed Central  Google Scholar 

Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J et al (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38(4):571–575

PubMed  Google Scholar 

Engkakul P, Mahachoklertwattana P, Jaovisidha S, Chuansumrit A, Poomthavorn P, Chitrapazt N et al (2013) Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol 35(3):212–217

PubMed  Google Scholar 

Cooper C, Dennison EM, Leufkens HG, Bishop N, Van Staa TP (2004) Epidemiology of Childhood fractures in Britain: a study using the General Practice Research Database. J Bone Min Res 19(12):1976–1981

Google Scholar 

Chen YG, Lu CS, Lin TY, Lin CL, Tzeng HE, Tsai CH (2018) Risk of fracture in transfusion-naïve thalassemia population: a nationwide population-based retrospective cohort study. Bone 106:121–125

PubMed  Google Scholar 

Yang R, Zou X, Zeng H, Zhao Y, Ma X (2020) Comparison of diagnostic performance of five different Ultrasound TI-RADS classification guidelines for thyroid nodules. Front Oncol 10:598225

PubMed  PubMed Central  Google Scholar 

Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Strauss BJ, Bowden D et al (2013) Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int 24(7):1965–1971

PubMed  Google Scholar 

Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D’Amore M (2009) Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with Thalassaemia major. Panminerva Med 51(1):17–23

PubMed  Google Scholar 

Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M et al (2004) Osteoprotegerin and RANKL in the Pathogenesis of Thalassemia-Induced osteoporosis: New Pieces of the Puzzle. J Bone Min Res 19(5):722–727

Google Scholar 

Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886):50–56

PubMed  PubMed Central  Google Scholar 

Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis A, Komninaka V et al (2012) High circulating sclerostin is Present in patients with thalassemia-associated osteoporosis and correlates with bone Mineral Density. Horm Metab Res 44(12):909–913

PubMed  Google Scholar 

Sapunarova K, Goranova-Marinova V, Georgiev P, Deneva T, Tsvetkova S, Grudeva-Popova Z (2020) Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia. Ann Med 52(3–4):94–108

PubMed  PubMed Central  Google Scholar 

Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Dimopoulou M, Komninaka V, Repa K et al (2019) Activin-A is elevated in patients with Thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density. Ann Hematol 98(7):1583–1592

PubMed  Google Scholar 

Singh K, Kumar R, Shukla A, Phadke SR, Agarwal S (2012) Status of 25-hydroxyvitamin D deficiency and effect of vitamin D receptor gene polymorphisms on bone mineral density in Thalassemia patients of North India. Hematology 17(5):291–296

PubMed  Google Scholar 

Arisal O, Deviren A, Fenerci EY, Hacihanefioglu S, Ulutin T, Erkmen S et al (2002) Polymorphism analysis in the COLIA1 gene of patients with Thalassemia major and intermedia. Haematologia (Budap) 32(4):475–482

PubMed  Google Scholar 

Dimitriadou M, Christoforidis A, Fidani L, Economou M, Perifanis V, Tsatra I et al (2011) Fok-I gene polymorphism of vitamin D receptor in patients with beta‐thalassemia major and its effect on vitamin D status. Hematology 16(1):54–58

PubMed  Google Scholar 

Langdahl G, Brixen E (2000) Polymorphisms in the vitamin D receptor gene and bone mass, bone turnover and osteoporotic fractures: VDR polymorphisms and osteoporosis. Eur J Clin Invest 30(7):608–617

PubMed  Google Scholar 

Ferrara M, Matarese SMR, Francese M, Borrelli B, Coppola A, Coppola L et al (2002) Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia: short report. Br J Haematol 117(2):436–440

PubMed  Google Scholar 

Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D’Agruma L et al (2000) Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 111(2):461–466

PubMed  Google Scholar 

Ragab SM, Badr EA, Ibrahim AS (2016) Evaluation of Glutathione-S-Transferase P1 polymorphism and its relation to bone Mineral Density in Egyptian Children and adolescents with Beta-Thalassemia Major. Mediterr J Hematol Infect Dis 8(1):e2016004

PubMed  PubMed Central  Google Scholar 

Yavropoulou MP, Anastasilakis AD, Tzoulis P, Tournis S, Rigatou E, Kassi E et al (2022) Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited: osteoporosis in β-thalassemia major. Acta Biomed Atenei Parmensis 93(5):e2022305

Google Scholar 

Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JCG et al (2014) Thalassemia bone disease: a 19-year longitudinal analysis. J bone Mineral Research: Official J Am Soc Bone Mineral Res 29(11):2468–2473

Google Scholar 

Mahachoklertwattana P, Pootrakul P, Chuansumrit A, Choubtum L, Sriphrapradang A, Sirisriro R et al (2006) Association between bone mineral density and erythropoiesis in Thai children and adolescents with Thalassemia syndromes. J Bone Min Metab 24(2):146–152

Google Scholar 

Cazzola M, De Stefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C et al (1995) Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 89(3):473–478

PubMed  Google Scholar 

Yamasaki K, Hagiwara H (2009) Excess iron inhibits osteoblast metabolism. Toxicol Lett 191(2–3):211–215

PubMed  Google Scholar 

Shen GS, Yang Q, Jian JL, Zhao GY, Liu LL, Wang X et al (2014) Hepcidin1 knockout mice display defects in bone microarchitecture and changes of bone formation markers. Calcif Tissue Int 94(6):632–639

PubMed  Google Scholar 

Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M et al (2003) Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 3(1):4

PubMed  PubMed Central  Google Scholar 

Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE et al (1994) Efficacy of Deferoxamine in preventing complications of Iron overload in patients with Thalassemia Major. N Engl J Med 331(9):567–573

PubMed  Google Scholar 

Chan YL, Pang LM, Chik KW, Cheng JC, Li CK (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Ped Radiol 32(7):492–497

Google Scholar 

Garofalo F, Piga A, Lala R, Chiabotto S, Stefano M, Isaia GC (1998) Bone metabolism in Thalassemiaa. Annals NY Acad Sci 850(1):475–478 COOLEY’S ANEM)

Google Scholar 

Bordbar M, Haghpanah S, Zekavat OR, Saki F, Bazrafshan A, Bozorgi H (2019) Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients. Expert Rev Hematol 12(11):997–1003

PubMed  Google Scholar 

Orvieto R, Leichter I, Rachmilewitz EA, Margulies JY (1992) Bone density, mineral content, and cortical index in patients with Thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif Tissue Int 50(5):397–399

PubMed  Google Scholar 

Bilgin BK, Yozgat AK, Isik P, Çulha V, Kacar D, Kara A et al (2020) The effect of deferasirox on endocrine complications in children with thalassemia. Pediatr Hematol Oncol 37(6):455–464

PubMed